Workflow
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
BMYBristol-Myers Squibb(BMY) Newsfilter·2024-02-28 20:34

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of 67.6millioninQ42023and67.6 million in Q4 2023 and 238.7 million in 2023; increasing commercial access to KIMMTRAK globally, and pursuing future growth opportunities with two registrational trials in advanced cutaneous melanoma and adjuvant uveal melanoma Clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) with nivolumab in regi ...